Holen Sie sich die Stockscreener-App
20.69
3.63%
-0.78
Handel nachbörslich:
20.75
0.06
+0.29%
Schlusskurs vom Vortag:
$21.47
Offen:
$21.245
24-Stunden-Volumen:
3.73M
Relative Volume:
1.48
Marktkapitalisierung:
$2.61B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-10.19
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-30.52%
1M Leistung:
-13.07%
6M Leistung:
+1.72%
1J Leistung:
-26.05%
1-Tages-Spanne:
$20.12
$21.41
1-Wochen-Bereich:
$19.25
$30.48
52-Wochen-Spanne:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
20.69 | 2.72B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals (APLS): Mizuho Adjusts Price Target and Rating Update | APLS Stock News - GuruFocus
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.Portfolio Value Report & Safe Swing Trade Setups - newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc.July 2025 Decliners & Smart Money Movement Alerts - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedJuly 2025 Market Mood & Safe Entry Trade Reports - newser.com
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Movement Recap & AI Driven Stock Price Forecasts - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recoveryJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exitWeekly Market Summary & Safe Capital Allocation Plans - newser.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockTrade Performance Summary & Smart Swing Trading Techniques - newser.com
How interest rate cuts could boost Apellis Pharmaceuticals Inc. stock2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buy2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economyWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldEarnings Overview Report & Daily Stock Trend Reports - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdownEarnings Performance Report & Verified Short-Term Plans - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueEarnings Recap Summary & Weekly High Return Stock Opportunities - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates - MSN
Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure - Markets Mojo
Brighton Jones LLC Buys Shares of 16,539 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc. recovery potential after sell off2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com
Citigroup Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $45.00 at TD Cowen - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $45.00 by Analysts at HC Wainwright - MarketBeat
Robert W. Baird Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript - Insider Monkey
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.July 2025 Movers & Weekly High Return Opportunities - newser.com
Jennison Associates LLC Raises Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Y Intercept Hong Kong Ltd Has $2.84 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by AlphaQuest LLC - MarketBeat
How Apellis Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
APLS: Citigroup Lowers Price Target Amidst Maintained Buy Rating - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastDividend Cut Warnings & Free Wealth Planning Blueprints - earlytimes.in
APLS Analyst Rating Update: TD Cowen Adjusts Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Beats Estimates By $0.64 EPS - MarketBeat
Apellis Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:APLS) 2025-10-31 - Seeking Alpha
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings - Yahoo Finance
APLS Stock: Baird Raises Price Target to $52, Maintains Outperfo - GuruFocus
APLS: HC Wainwright & Co. Lowers Price Target, Maintains 'Buy' R - GuruFocus
What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockTrade Risk Assessment & Low Volatility Stock Recommendations - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. tradingMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):